← Leaderboards
Philip C Wong
Johns Hopkins University
$27,601,264
Attributed
$31,012,337
Total exposure
18
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,319,381 · 18
FDA$1,600,000 · 1
By mechanism
R01$13,426,684 · 7
P01$8,145,431 · 3
RF1$3,501,155 · 2
UH3$2,237,856 · 1
R61$2,208,827 · 1
P50$2,069,256 · 2
Top collaborators
- Thomas E. Lloyd5 shared
- Yun Li2 shared
- James Dale Berry1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Thomas E. Lloyd$7,156,262
- Frances J Northington$9,523,922
- Solomon H Snyder$44,504,082
- Peter N Devreotes$29,214,251
- Felipe Andrade$7,256,287
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposMouse ModelTherapeutic TargetBaseExhibitsNeurodegenerative DisordersNeuronsValidationAdultS DiseaseMutantBrainDesignAmyloidosisDementiaGenerationsAttenuatedMolecularNeuron LossHuman DiseasePathogenesisPlayPathologyGenes
Grant awards (70)
Loss of TDP-43 disrupts the prefrontal neural activity and circuitry: relevance for TDP-43 linked ADRD$736,565
R01 · FY2025 · NS
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.$448,276
R01 · FY2024 · AR · contact PI
A diagnostic biomarker for amyotrophic lateral sclerosis$1,600,000
U01 · FY2023 · FD · contact PI
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker$1,245,777
RF1 · FY2023 · NS · contact PI
Generation and characterization of a mouse model exhibiting beta-amyloidosis and tauopathy with nuclear depletion of TDP-43$600,411
R33 · FY2023 · NS · contact PI
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.$462,140
R01 · FY2023 · AR
Loss of TDP-43 disrupts the prefrontal neural activity and circuitry: relevance for TDP-43 linked ADRD$2,255,378
RF1 · FY2022 · NS
Functional Validation of TDP-43 splicing repression for frontotemporal degeneration$1,092,581
UH3 · FY2022 · NS · contact PI
Generation and characterization of a mouse model exhibiting beta-amyloidosis and tauopathy with nuclear depletion of TDP-43$667,007
R33 · FY2022 · NS · contact PI
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.$457,518
R01 · FY2022 · AR
Functional Validation of TDP-43 splicing repression for frontotemporal degeneration$1,145,275
UH3 · FY2021 · NS · contact PI
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.$448,277
R01 · FY2021 · AR
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.$413,993
R01 · FY2020 · AR
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker$405,000
R01 · FY2020 · NS · contact PI
Generation and characterization of a mouse model exhibiting beta-amyloidosis and tauopathy with nuclear depletion of TDP-43$2,208,827
R61 · FY2019 · NS · contact PI
Functional Validation of TDP-43 splicing repression for frontotemporal degeneration$1,462,754
UG3 · FY2019 · NS · contact PI
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker$405,000
R01 · FY2019 · NS · contact PI
A novel AD mouse model for target validation: Abeta accelerates tauopathy-dependent neuronal loss$206,868
P50 · FY2019 · AG · contact PI
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker$405,000
R01 · FY2018 · NS · contact PI
A novel AD mouse model for target validation: Abeta accelerates tauopathy-dependent neuronal loss$207,149
P50 · FY2018 · AG · contact PI
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker$405,000
R01 · FY2017 · NS · contact PI
A novel AD mouse model for target validation: Abeta accelerates tauopathy-dependent neuronal loss$206,979
P50 · FY2017 · AG · contact PI
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker$405,000
R01 · FY2016 · NS · contact PI
A novel AD mouse model for target validation: Abeta accelerates tauopathy-dependent neuronal loss$221,330
P50 · FY2016 · AG · contact PI
A novel AD mouse model for target validation: Abeta accelerates tauopathy-dependent neuronal loss$206,868
P50 · FY2015 · AG · contact PI
Mechanisms & Mouse Models of Amyotrophic Lateral Sclerosis$351,575
R01 · FY2011 · NS · contact PI
Beta-amyloid Modulation: Role of BACE1/BACE2$451,000
R01 · FY2010 · NS · contact PI
Mechanisms & Mouse Models of Amyotrophic Lateral Sclerosis$355,163
R01 · FY2010 · NS · contact PI
Beta-amyloid Modulation: Role of BACE1/BACE2$82,000
R01 · FY2010 · NS · contact PI
Alzheimers Disease Mechanism & Experimental Therapeutic$995,118
P01 · FY2009 · NS · contact PI
Beta-amyloid Modulation: Role of BACE1/BACE2$451,000
R01 · FY2009 · NS · contact PI
Biology and Therapeutic Value of Mammalian Aph-1 Homologues$369,431
P01 · FY2009 · NS · contact PI
Mechanisms & Mouse Models of Amyotrophic Lateral Sclerosis$358,750
R01 · FY2009 · NS · contact PI
Nicastrin: Physiological Role and Therapeutic Target Validation$311,784
P01 · FY2009 · NS · contact PI
SYNAPTIC ABNORMALITIES IN PERFORANT PATH & BACE1$270,303
P50 · FY2009 · AG · contact PI
Alzheimers Disease Mechanism & Experimental Therapeutic$966,142
P01 · FY2008 · NS · contact PI
Mechanisms & Mouse Models of Amyotrophic Lateral Sclerosis$358,750
R01 · FY2008 · NS · contact PI
Biology and Therapeutic Value of Mammalian Aph-1 Homologues$358,675
P01 · FY2008 · NS · contact PI
Nicastrin: Physiological Role and Therapeutic Target Validation$302,709
P01 · FY2008 · NS · contact PI
SYNAPTIC ABNORMALITIES IN PERFORANT PATH & BACE1$256,944
P50 · FY2008 · AG · contact PI
Alzheimers Disease Mechanism & Experimental Therapeutic$965,650
P01 · FY2007 · NS · contact PI
Nicastrin and Presenilin-dependent gamma-secretase$368,191
R01 · FY2007 · NS · contact PI
Biology and Therapeutic Value of Mammalian Aph-1 Homologues$358,481
P01 · FY2007 · NS · contact PI
Mechanisms & Mouse Models of Amyotrophic Lateral Sclerosis$358,477
R01 · FY2007 · NS · contact PI
Nicastrin: Physiological Role and Therapeutic Target Validation$302,547
P01 · FY2007 · NS · contact PI
SYNAPTIC ABNORMALITIES IN PERFORANT PATH & BACE1$239,146
P50 · FY2007 · AG · contact PI
Alzheimers Disease Mechanism & Experimental Therapeutic$962,716
P01 · FY2006 · NS · contact PI
Nicastrin and Presenilin-dependent gamma-secretase$379,188
R01 · FY2006 · NS · contact PI
Beta-amyloid Modulation: Role of BACE1/BACE2$379,188
R01 · FY2006 · NS · contact PI
Biology and Therapeutic Value of Mammalian Aph-1 Homologues$333,437
P01 · FY2006 · NS · contact PI
Nicastrin: Physiological Role and Therapeutic Target Validation$281,407
P01 · FY2006 · NS · contact PI
SYNAPTIC ABNORMALITIES IN PERFORANT PATH & BACE1$128,669
P50 · FY2006 · AG · contact PI
Alzheimers Disease Mechanism &Experimental Therapeutic$1,017,418
P01 · FY2005 · NS
Nicastrin and Presenilin-dependent gamma-secretase$388,313
R01 · FY2005 · NS
Beta-amyloid Modulation: Role of BACE1/BACE2$388,313
R01 · FY2005 · NS
Biology and Therapeutic Value of Mammalian Aph-1 Homologues$335,111
P01 · FY2005 · NS
Nicastrin: Physiological Role and Therapeutic Target Validation$284,805
P01 · FY2005 · NS
SYNAPTIC ABNORMALITIES IN PERFORANT PATH &BACE1$125,000
P50 · FY2005 · AG
Beta-amyloid Modulation: Role of BACE1/BACE2$388,313
R01 · FY2004 · NS
Nicastrin and Presenilin-dependent gamma-secretase$388,313
R01 · FY2004 · NS
ROLE OF COPPER CHAPERONE FOR SOD1 IN MODELS OF ALS$286,125
R01 · FY2004 · NS
Beta-amyloid Modulation: Role of BACE1/BACE2$388,313
R01 · FY2003 · NS
Nicastrin and Presenilin-dependent gamma-secretase$388,313
R01 · FY2003 · NS
ROLE OF COPPER CHAPERONE FOR SOD1 IN MODELS OF ALS$286,125
R01 · FY2003 · NS
Beta-amyloid Modulation: Role of BACE1/BACE2$388,313
R01 · FY2002 · NS
ROLE OF COPPER CHAPERONE FOR SOD1 IN MODELS OF ALS$286,125
R01 · FY2002 · NS
ROLE OF COPPER CHAPERONE FOR SOD1 IN MODELS OF ALS$286,125
R01 · FY2001 · NS
REGULATION AND FUNCTION OF COPPER CHAPERONE FOR SOD1$198,975
R01 · FY2001 · NS
ROLE OF COPPER CHAPERONE FOR SOD1 IN MODELS OF ALS$286,344
R01 · FY2000 · NS
REGULATION AND FUNCTION OF COPPER CHAPERONE FOR SOD1$193,623
R01 · FY2000 · NS